Epidemiology, Immunology and Clinical Characteristics of COVID-19 (EPIC3)

CompletedOBSERVATIONAL

Enrollment

2,824

Participants

Timeline

Start Date

July 22, 2020

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions

SARS-CoV-2COVID-19

Trial Locations (1)

VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto

All Listed Sponsors

lead

VA Office of Research and Development

FED

NCT05764083 - Epidemiology, Immunology and Clinical Characteristics of COVID-19 (EPIC3) | Biotech Hunter | Biotech Hunter